

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(D) OF THE  
SECURITIES EXCHANGE ACT OF 1934

Date of Report (date of earliest event reported): **November 15, 2023**

**vTv Therapeutics Inc.**

(Exact name of registrant as specified in its charter)

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-37524**  
(Commission File No.)

**47-3916571**  
(IRS Employer  
Identification No.)

**3980 Premier Drive, Suite 310**  
**High Point, NC 27265**  
(Address of principal executive offices)

**(336) 841-0300**  
(Registrant's telephone number, including area code)

**NOT APPLICABLE**  
(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)  
 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)  
 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))  
 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Class A common stock, par value \$0.01 per share	VTVT	NASDAQ Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01 Regulation FD Disclosure**

On November 15, 2023, vTv Therapeutics, Inc., (the "Company") posted on its website an updated slide presentation, which is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. Representatives of the Company will use the presentation in various meetings with investors, analysts and other parties from time to time. This presentation may be amended or updated at any time and from time to time through another Current Report on Form 8-K, a later Company filing or other means.

The information in this Item 7.01 (including Exhibit 99.1) shall not be deemed to be "filed" for purposes of, or otherwise subject to the liabilities of, Section 18 of the Exchange Act, nor shall it be deemed to be incorporated by reference in any filing under the 33 Act or the Exchange Act, except as shall be expressly set forth by specific reference in any such filing.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

Exhibit No.	Description
99.1	<a href="#">vTv Therapeutics' Investor Presentation dated November 2023</a>
104	Cover Page Interactive Data File (embedded within Inline XBRL document)

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

**VTV THERAPEUTICS INC.**

By:	<u>          /s/ Paul J. Sekhri          </u>
Name:	Paul J. Sekhri
Title:	President and Chief Executive Officer

Dated: November 15, 2023



NASDAQ: VTVT

# Improving the Lives of Millions of Patients with Type 1 Diabetes

---

---

THE STATEMENTS MADE IN THIS PRESENTATION AND THE ACCOMPANYING ORAL COMMENTARY MAY INCLUDE FORWARD-LOOKING STATEMENTS REGARDING (I) DIABETES MARKET AND OTHER MARKETS, (II) THE DEVELOPMENT, CLINICAL TRIAL PROCESS, REGULATORY APPROVAL PROCESS AND ATTRIBUTES OF INVESTIGATIONAL AND MARKETED PRODUCTS TO TREAT THESE DISEASES AND OTHER CONDITIONS, (III) THE ECONOMIC POTENTIAL OF THOSE PRODUCTS AND (IV) THE FUTURE OPERATIONS, FUND-RAISING ACTIVITIES, EXPENDITURES, OPPORTUNITIES, AND FINANCIAL PERFORMANCE OF VTV THERAPEUTICS INC. FORWARD-LOOKING STATEMENTS INCLUDE ALL STATEMENTS THAT ARE NOT HISTORICAL FACTS AND CAN BE IDENTIFIED BY TERMS SUCH AS "ANTICIPATES," "BELIEVES," "COULD," "SEEKS," "ESTIMATES," "EXPECTS," "INTENDS," "MAY," "PLANS," "POTENTIAL," "PREDICTS," "PROJECTS," "SHOULD," "WILL," "WOULD" OR SIMILAR EXPRESSIONS AND THE NEGATIVES OF THOSE TERMS.

THESE FORWARD-LOOKING STATEMENTS ARE ONLY ESTIMATES BASED UPON THE INFORMATION AVAILABLE TO VTV THERAPEUTICS INC. (OR THE PARTY PREPARING SUCH FORWARD-LOOKING STATEMENTS) AS OF THE DATE OF THIS PRESENTATION. THE FORWARD-LOOKING STATEMENTS INCLUDED HEREIN INVOLVE KNOWN AND UNKNOWN RISKS AND UNCERTAINTIES AND OTHER IMPORTANT FACTORS SUCH THAT ACTUAL FUTURE OPERATIONS, OPPORTUNITIES, PRODUCT DEVELOPMENT PROCESSES AND OUTCOMES, CLINICAL TRIAL PROCESSES AND OUTCOMES, REGULATORY APPROVAL PROCESSES AND OUTCOMES, ECONOMIC PERFORMANCE OF PRODUCTS, FUND-RAISING ACTIVITIES AND FINANCIAL PERFORMANCE MAY DIFFER MATERIALLY FROM THOSE SET FORTH IN OR IMPLIED IN THESE FORWARD-LOOKING STATEMENTS. THESE RISKS, UNCERTAINTIES, AND OTHER FACTORS, WHICH MAY NOT BE WITHIN OUR CONTROL, ARE DISCUSSED IN MORE DETAIL IN OUR QUARTERLY, ANNUAL AND CURRENT REPORTS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION, INCLUDING, WITHOUT LIMITATION, UNDER THE CAPTIONS, "RISK FACTORS," "CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS" AND "MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS." THEREFORE, YOU SHOULD READ THIS PRESENTATION IN CONJUNCTION WITH SUCH MEANINGFUL CAUTIONARY STATEMENTS.


UNDUE RELIANCE SHOULD NOT BE PLACED ON FORWARD-LOOKING STATEMENTS, WHICH SPEAK ONLY AS OF THE DATE HEREOF. EXCEPT AS REQUIRED BY LAW, WE EXPRESSLY DISCLAIM ANY RESPONSIBILITY TO PUBLICLY UPDATE OR REVISE OUR FORWARD-LOOKING STATEMENTS, WHETHER AS A RESULT OF NEW INFORMATION, FUTURE EVENTS OR OTHERWISE. ALL FORWARD-LOOKING STATEMENTS CONTAINED HEREIN ARE QUALIFIED IN THEIR ENTIRETY BY THE FOREGOING CAUTIONARY STATEMENTS.

THIS PRESENTATION IS BEING PROVIDED TO YOU FOR INFORMATION PURPOSES ONLY. THIS PRESENTATION DOES NOT CONSTITUTE AN OFFER OR SALE OF (OR THE SOLICITATION OF AN OFFER TO BUY) ANY SECURITIES OF VTV THERAPEUTICS INC. OR ANY OF ITS SUBSIDIARIES.

BY ACCEPTING THIS PRESENTATION, YOU ACKNOWLEDGE AND AGREE THAT (I) YOU WILL NOT RELY ON THIS PRESENTATION FOR MAKING ANY INVESTMENT DECISION WITH RESPECT TO ANY SECURITIES OF VTV THERAPEUTICS INC. OR ANY OF ITS SUBSIDIARIES, AND (II) ANY INVESTMENT DECISION MADE BY YOU WITH RESPECT TO ANY SUCH SECURITIES WILL BE BASED SOLELY ON AN OFFERING DOCUMENT RELATING TO SUCH SECURITIES (IF ANY), INCLUDING THE INFORMATION INCORPORATED BY REFERENCE THEREIN.

---

## New Leadership Builds upon Decades of Scientific & Clinical Expertise




## Distinguished SAB Continues to Support Development of Cadisegliatin (TTP399)



**John Buse, MD, PhD**  
Verne S. Caviness Distinguished Professor  
Director, Diabetes Center  
Director, NC Translational & Clinical Sciences Institute



**G. Alexander "Zan" Fleming, MD**  
Founder & Executive Chairman, Kinexum  
Former FDA Supervisory Physician for Diabetes



**Justin Gregory, MD, MSci**  
Asst. Professor of Pediatrics  
Pediatric Endocrinology



**Gary Koch, PhD**  
Professor, Department of Biostatistics  
Director, Biometric Consulting Laboratory



**Robert Rizza, MD**  
Emeritus Professor of Medicine  
Division of Endocrinology, Diabetes,  
Metabolism & Nutrition




**Jay Skyler, MD, MACP, FRCP**  
Professor of Medicine, Pediatrics, & Psychology  
Division of Endocrinology, Diabetes, & Metabolism  
Deputy Director for Clinical Research & Academic  
Programs, Diabetes Research Institute



---


## Living with T1D is Like Driving Too Fast on a Dangerous Road

~80% of patients fail to achieve adequate blood glucose control. Fear of hypoglycemia is so intense that many accept high blood glucose, risking long-term health consequences and diabetic ketoacidosis (DKA).






## Hypoglycemia: The Plague of T1D



<sup>1</sup> Cyper PE. The burden of hypoglycemia in diabetes. *Diabetes*. 2008;57(12):2489-96.  
<sup>2</sup> Jolly AM, Beck RW, Anderson RM, Clements MA, Rickels MR, D'Alagni LA, Monda DM, Tamborlane WC, Bergenstal R, Smith G, Olson RK, Garg SK. State of Type 1 Diabetes Management and Outcomes from the T1D Exchange in 2016-2018. *Diabetes Technol Ther*. 2019.  
<sup>3</sup> JGIM. Medical Research 2018.  
<sup>4</sup> Pappas M, Barlett AE, Wanghila UT, Schumm-Draeger PM. Insulin adherence: Barriers and drivers in the real-world: Global Attitudes of Patients and Physicians in Health Therapy study. *Diabet Med*. 2012; May; 29(5):682-8. doi: 10.1111/j.1464-5448.2012.02860.x. PMID: 22333232. PMID: 24131794

## Cadiseqliatin is the First Liver-Selective Glucokinase Activator to Reach Phase 3



---


**Cadisegliatin:**

A First In Class Adjunctive Therapy to Insulin for the Treatment of Type 1 Diabetes


A Liver-Selective Glucokinase Activator that:

- 1) Reduces the Risk of Hypoglycemia
- 2) Improves Glycemic Control


## In Healthy Patients, the Liver Acts as a Reservoir for Glucose



## With Type 1 Diabetes, Glucokinase Activity in the Liver is Impaired




## Cadiseqliatin Reactivates Innate Glucose-Regulating Capacity of the Liver



## Our Simplici1 Trial Demonstrated Statistically & Clinically Significant Efficacy & Confirmed Safety

Trials sponsored in part by:  
**JDRF**  
IMPROVING  
LIVES  
BY  
CURING  
TYPE 1  
DIABETES.




Randomized, Double-Blind, Placebo Controlled 2-Part Study of ~100 patients. A total of 46 patients in the treatment groups received 800mg daily of cadiseglatin.

Study Details: <https://diabetesjournals.org/care/article/44/4/960/138590/The-Simplici1-Study-A-Randomized-Double-Blind> & <https://clinicaltrials.gov/ct2/show/NCT03335371>

---

Cadisegliatin MoA of reducing hyperglycemic stress could be complementary to other interventions in T1D, in addition to preventing the long-term sequelae of both hyper- and hypoglycemia





---

## High Level Commercial Opportunity Assessment

**\$1.7B - \$2.8B**

Peak U.S. Sales Opportunity

***Further Upside:***






Ex-US Markets;  
T2D indication adds ~2.8M lives

- ◆ **Base Case** Cadisegliatin Product Profile  
(≥ 30% reduction hypoglycemic episodes; Δ HbA1c ≥ -0.5%)
- ◆ **1.6M** people, **growing 2.9%** annually <sup>1</sup>
- ◆ **\$600 Monthly WAC** <sup>2</sup>
- ◆ **2028** Product Launch <sup>3</sup>
- ◆ **15% - 25%** peak population uptake <sup>3</sup>
- ◆ **70%** adherence rate <sup>3</sup>

<sup>1</sup> Type 1 Diabetes Index website. Available at <https://t1diabetes.org>. Accessed on September 28th, 2023.  
<sup>2</sup> Prescription Drug Disclosure program. Fresco WAC. Available at <https://www.fresco.org/medication-drug-price-disclosure-program>  
<sup>3</sup> Internal, vTv Therapeutics



## Pipeline Creates Additional Upside

vTv Partner vTv + Partner

PRODUCT	PRE-CLINICAL	PHASE I	PHASE II	PHASE III	PARTNERS + REGIONS
<b>Cadiseqliatin (TTP399)</b> GK Activator	Type 1 Diabetes				 Certain countries in the Middle East, Africa, and Central Asia
	Type 2 Diabetes				
<b>TTP273</b> Oral GLP-1R Agonist	Cystic Fibrosis-Related Diabetes				 Asia (excl. Japan)
	Type 2 Diabetes				
<b>HPP737</b> PDE4 Inhibitor	SAD/MAD Completed				 Asia (excl. Japan)
	Psoriasis / COPD / Atopic Dermatitis				
<b>Mavodelpar (HPP593)</b> PPAR-δ Agonist	Primary Mitochondrial Myopathies (PMM)				 Worldwide
	Long-chain fatty acid oxidation disorders (LC-FAOD)				
<b>Azeliragon</b> RAGE Antagonist	Glioblastoma / Other Cancers and Cancer Treatment-Related Conditions				 Worldwide
<b>HPP3033</b> Nrf2/Bach1 Modulator	Undisclosed				
<b>TTP-RA</b> RAGE Antagonist	Type 1 Diabetes Prevention				

---

We Have the Opportunity to Ease the Burden of Managing T1D and Improve the Lives of Patients Living with Type 1 Diabetes



---

## Conclusions



Cadiseqliatin significantly improved glycemic control



Cadiseqliatin had a favorable safety profile: reduction of hypoglycemia and ketosis events



**FDA has granted cadiseqliatin Breakthrough Designation for the Treatment of T1D**



Poised to initiate phase 3 trials for cadiseqliatin

